Security record · archived quarter
CTMX
CytomX Therapeutics, Inc. · Healthcare · Biotechnology
1Tracked holders
0Δ holders
1.18MShares held
$3.21MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 1.18M | $3.21M | n/a | n/a |
| Q2 2026 | 73 | +11 | 136.41M | $511.64M | +18 | −7 |
| Q1 2026 | 64 | +15 | 111.19M | $522.57M | +20 | −5 |
| Q4 2025 | 49 | -1 | 71.30M | $303.77M | n/a | −1 |
| Q3 2025 | 14 | 0 | 41.38M | $131.99M | n/a | n/a |
| Q2 2025 | 11 | 0 | 36.17M | $82.10M | n/a | n/a |
| Q1 2025 | 8 | +1 | 8.01M | $5.09M | +1 | n/a |
| Q4 2024 | 7 | 0 | 9.00M | $9.27M | +1 | −1 |
| Q3 2024 | 6 | 0 | 8.17M | $9.64M | n/a | n/a |
| Q2 2024 | 6 | n/a | 7.95M | $9.70M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 1.18M | +62.2% | $3.21M | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 178 holders, 193.14M shares, $906.86M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API